MedTrace Logo

Simplified Antiviral Treatment Strategy for Hepatitis C in Myanmar

NCT03579576 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 803

Last updated 2019-07-29

No results posted yet for this study

Summary

The project will evaluate cost and treatment outcomes of a simplified hepatitis C virus (HCV) testing, treatment and care model integrated with HIV testing and treatment among key affected populations including people who inject drugs (PWID) in Myanmar.

Conditions

Interventions

DRUG

sofosbuvir 400 mg/velpatasvir 100 mg (SOF/VEL) orally once daily for 12 weeks with or without weight-based ribavirin.

Direct Acting anti-HCV drugs given to all HCV infected participants at baseline.Those with Co-infections like HIV and or HBV will be given treatment as per national guidelines.

Sponsors & Collaborators

  • Community Partners International

    collaborator OTHER

  • Myanmar Liver Foundation

    collaborator OTHER

  • Boston University

    collaborator OTHER

  • University of California, Los Angeles

    collaborator OTHER

  • Ministry of Health and Sports, Myanmar

    collaborator OTHER_GOV

  • Right to Care

    lead OTHER

Principal Investigators

  • Ian Sanne, MBBCH,FRCP · Right to Care

  • Khin Pyone Khi, MBBS,FRCP,PhD · Myanmar Liver Foundation

  • Charles Chasela, PhD · Right to Care

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-20
Primary Completion
2019-03-30
Completion
2019-06-30

Countries

  • Burma

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03579576 on ClinicalTrials.gov